Document:

Exhibit 10.5

 

SUBSCRIPTION AGREEMENT

 

PN Med Group Inc.1

San Isidro 250, Depot 618

Santiago, Chile 8240400

 

This Subscription Agreement (this “Agreement”)
has been executed by the subscriber set forth on the signature page hereof (the “Subscriber”) in connection
with the private placement offering (the “Offering”) of a minimum of $12,000,000 (the “Minimum
Offering”) and a maximum of $20,000,000 (the “Maximum Offering”) of Units of securities
(the “Units”), plus up to an additional $5,000,000 of Units to cover over-allotments, issued by PN Med
Group Inc., a Nevada corporation (the “Company”), at a purchase price of $1.00 per Unit (the “Purchase
Price”). Each Unit consists of (i) one share of the Company’s common stock, par value $0.001 per share (“Common
Stock”), and (ii) a warrant, substantially in the form of Exhibit A hereto (the “Warrant”),
representing the right to purchase one share of Common Stock, exercisable from issuance until five (5) years after the initial
Closing of the Offering at an exercise price of $2.00 per share. This subscription is being submitted to you in accordance with
and subject to the terms and conditions described in this Agreement, the Confidential and Non-Binding Summary Term Sheet of the
Company dated November 27, 2013, relating to the Offering (as the same may be amended or supplemented, the “Term Sheet”),
the Confidential Private Placement Memorandum of the Company dated December 6, 2013 (as the same may be amended or supplemented,
the “PPM”), and any other Disclosure Materials (as defined below). The minimum subscription is $100,000
(100,000 Units). The Company may accept subscriptions for less than $100,000 in its sole discretion.

 

The Units being subscribed for pursuant
to this Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”).
The Offering is being made on a reasonable best efforts basis to “accredited investors,” as defined in Regulation D
under the Securities Act.

 

The Units are being offered and sold in
connection with a reverse triangular merger (the “Merger”) between a subsidiary of the Company and Ekso
Bionics, Inc., a Delaware corporation (“Ekso”), and certain other transactions, on the terms and
conditions described in the PPM, pursuant to which Ekso will become a wholly owned subsidiary of the Company, and all of the outstanding
Ekso stock will be converted into shares of the Company’s Common Stock, and Ekso stock options and warrants will be converted
into options and warrants to purchase the Company’s Common Stock, as further described in the PPM. Prior to the first Closing
(as defined below), the Company intends to change its name to “Ekso Bionics Holdings, Inc.” or another name that reflects
its intended new business.

 

In November 2013, Ekso completed a private
placement to accredited investors of $5,000,000 of its senior subordinated secured convertible notes (the “Bridge Notes”).
Upon closing of the Merger and the Minimum Offering, (i) the Bridge Notes will convert into 5,000,000 Units, and (ii) the holders
of Bridge Notes will also receive warrants to purchase 2,500,000 shares of Common Stock, at an exercise price of $1.00 per share
for a term of three (3) years (the “Bridge Warrants”). The aggregate principal amount of Bridge Notes
(as defined below) converted upon the Merger will be included in the gross proceeds of the Offering for purposes of meeting the
Minimum Offering and the Maximum Offering amounts.

 

The undersigned acknowledges receipt of
a copy of the Registration Rights Agreement, substantially in the form of Exhibit B hereto (the “Registration
Rights Agreement”).

 

 

1 Intended to be renamed Ekso
Bionics Holdings, Inc.

 

    	 

    	 

    

 

Each closing of the Offering (a “Closing,”
and the date on which such Closing occurs hereinafter referred to as the “Closing Date”) shall take place
at the offices of Gottbetter & Partners, LLP, at 488 Madison Avenue, New York, New York 10022 (or such other place as is mutually
agreed to by the Company and the Placement Agent (as defined below)).

 

The initial Closing will not occur unless:

 

		a.	funds deposited in escrow as described in Section 2(b) below equal at least the Minimum Offering,
and corresponding documentation with respect to such amounts has been delivered by Subscribers as described in Section 2(a) below;
and

 

		b.	the Merger shall have been effected (or is simultaneously effected).

 

Thereafter, the Company may conduct one
or more additional Closings for the sale of the Units until the termination of the Offering. Unless terminated earlier by the Company,
the Offering shall continue until December 20, 2013, which date may be extended until January 17, 2014, by the Company, without
notice to any Subscriber, past, current or prospective.

 

The PPM, the Term Sheet and any supplement
or amendment thereto, and any disclosure schedule or other information document, delivered to the Subscriber prior to Subscriber’s
execution of this Agreement, and any such document delivered to the Subscriber after Subscriber’s execution of this Agreement
and prior to the Closing of the Subscriber’s subscription hereunder, are collectively referred to as the “Disclosure
Materials.”

 

		1.	Subscription. The undersigned Subscriber hereby subscribes to purchase the number of Units
set forth on the Omnibus Signature Page attached hereto, for the aggregate Purchase Price as set forth on such Omnibus Signature
Page, subject to the terms and conditions of this Agreement and on the basis of the representations, warranties, covenants and
agreements contained herein.

 

		2.	Subscription Procedure. To complete a subscription for the Units, the Subscriber must fully
comply with the subscription procedure provided in this Section on or before the Closing Date.

 

		a.	Subscription Documents. On or before the Closing Date, the Subscriber shall review, complete
and execute the Omnibus Signature Page to this Agreement, the Investor Profile, Anti-Money Laundering Form and Investor Certification,
attached hereto following the Omnibus Signature Page (collectively, the “Subscription Documents”), and
deliver the Subscription Documents to the Company’s attorneys, Gottbetter & Partners, LLP (“G&P”),
at the address set forth under the caption “How to subscribe for Units in the private offering of PN Med Group Inc.”
below. Executed documents may be delivered to G&P by facsimile or electronic mail (e-mail), if the Subscriber delivers the
original copies of the documents to G&P as soon as practicable thereafter.

 

		b.	Purchase Price. Simultaneously with the
delivery of the Subscription Documents to G&P as provided herein, and in any event on or prior to the Closing Date, the Subscriber
shall deliver to CSC Trust Company of Delaware, in its capacity as escrow agent (the “Escrow Agent”),
the full Purchase Price by certified or other bank check or by wire transfer of immediately available funds, pursuant to the instructions
set forth under the caption “How to subscribe for Units in the private offering of PN Med Group Inc.” below.Such
funds will be held for the Purchaser’s benefit and will be returned promptly, without interest or offset, if this Subscription
Agreement is not accepted by the Company or the Offering is terminated pursuant to its terms by the Company prior to the Closing
as defined herein.

 

    	2

    	 

    

 

		c.	Company Discretion. The Subscriber understands and agrees that the Company in its sole discretion
reserves the right to accept or reject this or any other subscription for Units, in whole or in part, notwithstanding prior receipt
by the Subscriber of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the Company
shall execute and deliver to the Subscriber an executed copy of this Agreement. If this subscription is rejected in whole, or the
offering of Units is terminated, all funds received from the Subscriber will be returned without interest or offset, and this Agreement
shall thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion
of this subscription will be returned without interest or offset, and this Agreement will continue in full force and effect to
the extent this subscription was accepted.

 

		3.	Placement Agent. Gottbetter Capital Markets, LLC, a broker-dealer
licensed with the FINRA, has been engaged on an exclusive basis as placement agent (the “Placement Agent”)
for the Offering on a reasonable best efforts basis. The Placement Agent will be paid at closing a cash commission of 10% (or 2%
in the case of certain named investors) of funds raised from investors introduced to the Offering by it and will receive warrants
to purchase a number of shares of Common Stock equal to 10% (or 2% in the case of certain named investors) of the number of Units
sold in the Offering to investors introduced to the Offering by it, with a term of five (5) years and at an exercise price of $1.00
per share (the “Placement Agent Warrants”). In connection with the sale of the Bridge Notes, Ekso paid
the Placement Agent and its sub-agent, a cash commission of 10% of the funds raised and agreed to cause the Company issue to them,
upon the closing of the Merger and the Minimum Offering, warrants to purchase a number of shares of the Company’s common
stock equal to 10% of the number of shares of Common Stock into which the Bridge Notes will convert at the closing of the Minimum
Offering, with a term of five (5) years, at an exercise price of $1.00 per share (the “Bridge Placement Agent Warrants”).
The Placement Agent will be paid an additional cash commission of 5% of funds received by the Company
from the exercise of Bridge Warrants (as defined in the PPM) and Warrants issued to investors introduced by it resulting from a
solicitation of the exercise of such warrants by the Company. Any sub-agent of the Placement Agent that introduced investors to
the Bridge Notes or introduces investors to the Offering will be entitled to share in the cash fees and warrants attributable to
those investors as described above, pursuant to the terms of an executed sub-agent agreement).

 

		4.	Representations and Warranties of the Company. The Company hereby represents and warrants
to the Subscriber the following:

 

		a)	Organization and Qualification. The Company and each of
its subsidiaries is a corporation or other business entity duly organized and validly existing in good standing under the laws
of the jurisdiction of its formation, and has the requisite corporate power to own its properties and to carry on its business
as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and
is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect, as defined
below. Each subsidiary of the Company, after giving effect to the Merger, is identified on Schedule 4a attached hereto.
(For purposes of the representations and warranties contained in this Section 4, the term “Subsidiary”
as applied to the Company includes Ekso and its subsidiaries on a pro forma basis giving effect to the Merger.

 

    	3

    	 

    

 

		b)	Authorization, Enforcement, Compliance with Other Instruments.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement,
the Warrants, the Registration Rights Agreement and each of the other agreements and documents that are exhibits hereto or thereto
or are contemplated hereby or thereby or necessary or desirable to effect the transactions contemplated hereby or thereby (the
“Transaction Documents”) and to issue the shares of Common Stock contained in the Units (the “Shares”)
and the Warrants, and the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”),
in accordance with the terms hereof and thereof, (ii) the execution and delivery by the Company of each of the Transaction Documents
and the consummation by it of the transactions contemplated hereby and thereby, including, without limitation, the issuance of
the Shares, the Warrants and the Warrant Shares, have been, or will be at the time of
execution of such Transaction Document, duly authorized by the Company’s Board of Directors, and no further consent or authorization
is, or will be at the time of execution of such Transaction Document, required by the Company, its respective Board of Directors
or its stockholders, (iii) each of the Transaction Documents will be duly executed and delivered by the Company, (iv) the Transaction
Documents when executed will constitute the valid and binding obligations of the Company enforceable against the Company in accordance
with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies.

 

		c)	Capitalization. The authorized capital stock of the Company
currently consists of 75,000,000 shares of Common Stock and no shares of preferred stock, and prior to the Merger, the authorized
capital stock of the Company will consist of 500,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. As of
the date hereof the Company has 6,350,000 shares of Common Stock issued and outstanding. All of the outstanding shares of Common
Stock and of the stock of each of the Company’s Subsidiaries have been duly authorized, validly issued and are fully paid
and nonassessable. After giving effect to the Merger: (i) no shares of capital stock of the Company or any of its Subsidiaries
will be subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company;
(ii) no shares of capital stock of the Company or any of its Subsidiaries will be subject to preemptive rights or any other similar
rights or any liens or encumbrances suffered or permitted by the Company; (iii) there will be no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements
by which the Company or any of its subsidiaries is or may become bound to issue additional shares of capital stock of the Company
or any of its subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, in
each case, other than as set forth under “Pro Forma Capitalization” in the PPM, (iv) there will be no outstanding
debt securities other than indebtedness as set forth in Schedule 4n, (v) other than pursuant to the Registration Rights Agreement,
there will be no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale
of any of their securities under the Securities Act, and (vi) there will be no outstanding registration statements, and there will
be no outstanding comment letters from the SEC or any other regulatory agency; (vii) except as provided in this Agreement, there
are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Units
as described in this Agreement; (viii) no co-sale right, right of first refusal or other similar right exists with respect to the
Units (or will exist with respect to the Warrant Shares) or the issuance and sale thereof; and (ix) the issue and sale of the Units
(and the Warrant Shares) will not result in a right of any holder of Company securities to adjust the exercise, exchange or reset
price under such securities. Immediately after giving effect to the Merger and the Closing of the Minimum Offering or the Maximum
Offering, the pro forma outstanding capitalization of the Company will be as set forth under “Pro Forma Capitalization”
in the PPM. Upon request, the Company will make available to the Subscriber true and correct copies of the Company’s Certificate
of Incorporation, and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s
By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities exercisable for Common Stock
and the material rights of the holders thereof in respect thereto other than stock options issued to employees and consultants.

 

    	4

    	 

    

 

		d)	Issuance of Securities. The Shares and the Warrants are
duly authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and
are free from all taxes, liens and charges with respect to the issue thereof. Upon issuance of the Warrant Shares upon exercise
of the Warrants, against payment therefor and in accordance with the terms of the Warrants, the Warrant Securities will be duly
issued, fully paid and nonassessable, and will be free from all taxes, liens and charges with respect to the issue thereof.

 

		e)	No Conflicts. The execution, delivery and performance
of each of the Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby
and thereby will not (i) result in a violation of the Certificate of Incorporation or the By-laws (or equivalent constitutive document)
of the Company or any of its Subsidiaries or (ii) violate or conflict with, or result in a breach of any provision of, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any Subsidiary
is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state
securities laws and regulations) applicable to the Company or any Subsidiary or by which any property or asset of the Company or
any Subsidiary is bound or affected except for those which could not reasonably be expected to have a material adverse effect on
the assets, business, condition (financial or otherwise), results of operations or future prospects of the Company and its Subsidiaries
taken as a whole (a “Material Adverse Effect”). Except those which could not reasonably be expected to have a Material
Adverse Effect, neither the Company nor any Subsidiary is in violation of any term of or in default under its constitutive documents.
Except those which could not reasonably be expected to have a Material Adverse Effect, neither the Company nor any Subsidiary is
in violation of any term of or in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order or any statute, rule or regulation applicable to the Company or any Subsidiary. The business of the Company
and its Subsidiaries is not being conducted, and shall not be conducted in violation of any material law, ordinance, or regulation
of any governmental entity, except for any violation which could not reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act
and any applicable state securities laws, neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization
or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or perform
any of its obligations under or contemplated by this Agreement or the other Transaction Documents in accordance with the terms
hereof or thereof. Except as set forth on Schedule 4e, neither the execution and delivery by the Company of the Transaction Documents,
nor the consummation by the Company of the transactions contemplated hereby or thereby, will require any notice, consent or waiver
under any contract or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is
bound or to which any of their assets is subject, except for any notice, consent or waiver the absence of which would not have
a Material Adverse Effect and would not adversely affect the consummation of the transactions contemplated hereby or thereby. All
consents, authorizations, orders, filings and registrations which the Company or any of its Subsidiaries is required to obtain
pursuant to the preceding two sentences have been or will be obtained or effected on or prior to the Closing. The Company is unaware
of any facts or circumstance, which might give rise to any of the foregoing.

 

    	5

    	 

    

 

		f)	Absence of Litigation. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body now pending
or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, wherein an unfavorable
decision, ruling or finding would (i) adversely affect the validity or enforceability of, or the authority or ability of the Company
or any of its Subsidiaries to perform its obligations under, this Agreement or any of the other Transaction Documents, or (ii)
have a Material Adverse Effect.

 

		g)	Acknowledgment Regarding Subscriber’s Purchase of the
Units. The Company acknowledges and agrees that each Subscriber is acting solely in the capacity of an arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that each Subscriber is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by such Subscriber or any
of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
and thereby is merely incidental to such Subscriber’s purchase of the Units (and the Warrant Shares). The Company further
represents to the Subscribers that the Company’s decision to enter into the Transaction Documents has been based solely on
the independent evaluation by the Company and its representatives.

 

		h)	No General Solicitation. Neither the Company, nor any
of its affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the Units.

 

		i)	No Integrated Offering. Neither the Company, nor any of
its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would require registration of the Units or the securities
contained therein under the Securities Act or cause this offering of the Units or the securities contained therein to be integrated
with prior offerings by the Company for purposes of the Securities Act.

 

		j)	Employee Relations. Neither Company nor any Subsidiary
is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened. Neither Company nor any
Subsidiary is party to any collective bargaining agreement. The Company’s and/or its Subsidiaries’ employees are not
members of any union, and the Company and its Subsidiaries’ relationship with their respective employees is good.

 

    	6

    	 

    

 

		k)	Intellectual Property Rights. Except as set forth on Schedule
4k, the Company and its Subsidiaries own or possess all patents, trademarks, domain names (whether or not registered) and any patentable
improvements or copyrightable derivative works thereof, websites and intellectual property rights relating thereto, service marks,
trade names, copyrights, licenses and authorizations, and all rights with respect to the foregoing, which are necessary for the
conduct of its business as now conducted without any conflict with the rights of others except for such conflicts that would not
result in a Material Adverse Effect. Neither Company nor any Subsidiary has received any notice of infringement of, or conflict
with, the asserted rights of others with respect to any intellectual property that it utilizes.

 

		l)	Environmental Laws.

 

		(i)	The Company and each Subsidiary has complied with all applicable Environmental Laws (as defined
below), except for violations of Environmental Laws that, individually or in the aggregate, have not had and would not reasonably
be expected to have a Material Adverse Effect. There is no pending or, to the knowledge of the Company, threatened civil or criminal
litigation, written notice of violation, formal administrative proceeding, or investigation, inquiry or information request, relating
to any Environmental Law involving the Company or any Subsidiary, except for litigation, notices of violations, formal administrative
proceedings or investigations, inquiries or information requests that, individually or in the aggregate, have not had and would
not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, “Environmental Law” means
any national, state, provincial or local law, statute, rule or regulation or the common law relating to the environment or occupational
health and safety, including without limitation any statute, regulation, administrative decision or order pertaining to (i) treatment,
storage, disposal, generation and transportation of industrial, toxic or hazardous materials or substances or solid or hazardous
waste; (ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release or threatened release into
the environment of industrial, toxic or hazardous materials or substances, or solid or hazardous waste, including without limitation
emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants or chemicals; (v) the protection of wild
life, marine life and wetlands, including without limitation all endangered and threatened species; (vi) storage tanks, vessels,
containers, abandoned or discarded barrels, and other closed receptacles; (vii) health and safety of employees and other persons;
and (viii) manufacturing, processing, using, distributing, treating, storing, disposing, transporting or handling of materials
regulated under any law as pollutants, contaminants, toxic or hazardous materials or substances or oil or petroleum products or
solid or hazardous waste. As used above, the terms “release” and “environment” shall have the meaning set
forth in the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended.

 

		(ii)	To the knowledge of the Company there is no material environmental liability with respect to any
solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company or any Subsidiary.

 

		(iii)	The Company and its Subsidiaries (i) have received all permits, licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses and (ii) are in compliance with all terms and
conditions of any such permit, license or approval.

 

    	7

    	 

    

 

		m)	Permits; FDA Compliance. The Company and its Subsidiaries
have all authorizations, approvals, clearances, licenses, permits, certificates or exemptions (including manufacturing approvals
and authorizations, pricing and reimbursement approvals, labeling approvals, registration notifications or their foreign equivalent)
issued by any regulatory authority or governmental agency (collectively, “Permits”) required to conduct
their respective businesses as currently conducted except to the extent that the failure to have such Permits would not have a
Material Adverse Effect. The conduct of business by the Company complies, and at all times has substantially complied, in all material
respects with the Federal Food, Drug and Cosmetic Act (the “FDCA”) and similar federal, state and foreign
laws applicable to the evaluation, testing, manufacturing, distribution, advertising and marketing of each of the Company’s
medical device products, in whatever stage of development or commercialization except to the extent that the failure to so comply
would not have a Material Adverse Effect. To the knowledge of the Company, as of the date hereof, neither the United States Food
and Drug Administration (the “FDA”) nor any comparable regulatory authority or governmental agency is
considering limiting, suspending or revoking any such Permit or changing the marketing classification or labeling of the products
of the Company or any of its Subsidiaries. To the knowledge of the Company, there is no false or misleading information or material
omission in any product application or other submission by the Company or any of its Subsidiaries to the FDA or any comparable
regulatory authority or governmental agency. The Company or its Subsidiaries have fulfilled and performed in all material respects
their obligations under each Permit, and, as of the date hereof, to the knowledge of the Company, no event has occurred or condition
or state of facts exists which would constitute a breach or default or would cause revocation or termination of any such Permit
except to the extent that such breach, default, revocation or termination would not have a Material Adverse Effect. To the knowledge
of the Company, any third party that is a manufacturer or contractor for the Company or any of its Subsidiaries is in compliance
in all material respects with all Permits insofar as they pertain to the manufacture of product components or products for the
Company. The Company and its Subsidiaries have not received any Form FDA-483, notice of adverse finding, FDA warning letter, notice
of violation or “untitled letter,” notice of FDA action for import detention or refusal, or any other notice from the
FDA or other governmental agency alleging or asserting noncompliance with any applicable laws or Permits. The Company and its Subsidiaries
are not subject to any obligation arising under an administrative or regulatory action, FDA inspection, FDA warning letter, FDA
notice of violation letter or other notice, response or commitment made to or with the FDA or any comparable regulatory authority
or governmental agency. The Company and its Subsidiaries have made all notifications, submissions and reports required by the FDCA
or similar federal, state and foreign laws, except to the extent that the failure to make such notifications, submission or reports
would not have a Material Adverse Effect.

 

		n)	Title. Neither the Company nor any of its Subsidiaries
owns any real property. Except as set forth on Schedule 4n, each of the Company and its Subsidiaries has good and marketable title
to all of its personal property and assets free and clear of any material restriction, mortgage, deed of trust, pledge, lien, security
interest or other charge, claim or encumbrance which would have a Material Adverse Effect. Except as set forth on Schedule 4n,
with respect to properties and assets it leases, each of the Company and its Subsidiaries is in material compliance with such leases
and holds a valid leasehold interest free of any liens, claims or encumbrances which would have a Material Adverse Effect.

 

		o)	No Material Adverse Breaches, etc. Neither Company nor
any Subsidiary is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation
which in the judgment of the Company’s officers has or is expected in the future to have a Material Adverse Effect. Neither
Company nor any Subsidiary is in breach of any contract or agreement which breach, in the judgment of the Company’s officers,
has or is expected to have a Material Adverse Effect.

 

    	8

    	 

    

 

		p)	Tax Status. The Company and each Subsidiary has made and
filed (taking into account any valid extensions) all material federal and state income and all other material tax returns, reports
and declarations required by any jurisdiction to which it is subject and (unless and only to the extent that the Company or such
Subsidiary has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate
for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There
are no unpaid taxes in any material amount claimed to be due from the Company or any Subsidiary by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such claim.

 

		q)	Certain Transactions. Except for arm’s length transactions
pursuant to which the Company or any Subsidiary makes payments in the ordinary course of business upon terms no less favorable
than it could obtain from third parties, none of the officers, directors, or employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge
of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a
substantial interest or is an officer, director, trustee or partner.

 

		r)	Rights of First Refusal. Except as set forth on Schedule
4e, the Company is not obligated to offer the securities offered hereunder on a right of first refusal basis or otherwise to any
third parties including, but not limited to, current or former stockholders of the Company, underwriters, brokers, agents or other
third parties.

 

		s)	Reliance. The Company acknowledges that the Subscriber
is relying on the representations and warranties made by the Company hereunder and that such representations and warranties are
a material inducement to the Subscriber purchasing the Units. The Company further acknowledges that without such representations
and warranties of the Company made hereunder, the Subscribers would not enter into this Agreement.

 

		t.	Brokers’ Fees. Except as set forth on Schedule 4t, the Company does not have any liability
or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions contemplated by this
Agreement, except for the payment of fees to the Placement Agent as described below

 

		u.	SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Exchange Act of 1934, as amended, including pursuant to Section 13(a)
or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material).

 

    	9

    	 

    

 

		5.	Representations and Warranties of the Subscriber. The Subscriber represents and warrants
to the Company the following:

 

		a.	The Subscriber, its advisers, if any, and its designated representatives, if any, have the knowledge
and experience in financial and business matters necessary to evaluate the merits and risks of its prospective investment in the
Company, and have carefully reviewed and understand the risks of, and other considerations relating to, the purchase of Units and
the tax consequences of the investment, and have the ability to bear the economic risks of the investment.

 

		b.	The Subscriber is acquiring the Units, and upon exercise of the Warrants, the Warrant Shares, for
investment for its own account and not with the view to, or for resale in connection with, any distribution thereof. The Subscriber
understands and acknowledges that the Units, the Shares and the Warrants have not been, and the Warrant Shares will not be, registered
under the Securities Act or any state securities laws, by reason of a specific exemption from the registration provisions of the
Securities Act and applicable state securities laws, which depends upon, among other things, the bona fide nature of the investment
intent as expressed herein. The Subscriber further represents that it does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participation to any third person with respect to any of the Units, the Shares, the
Warrants or the Warrant Shares. The Subscriber understands and acknowledges that the offering of the Units pursuant to this Agreement
will not be registered under the Securities Act nor under the state securities laws on the ground that the sale provided for in
this Agreement and the issuance of securities hereunder is exempt from the registration requirements of the Securities Act and
any applicable state securities laws.

 

		c.	The Subscriber is an “accredited investor” as defined
in Rule 501 of Regulation D as promulgated by the Securities and Exchange Commission under the Securities Act, for the reason(s)
specified on the Accredited Investor Certification attached hereto as completed by Subscriber, and Subscriber shall
submit to the Company such further assurances of such status as may be reasonably requested by the Company. The Subscriber
resides in the jurisdiction set forth on the Subscriber’s Omnibus Signature Page affixed hereto.

 

		d.	The Subscriber (i) if a natural person, represents that he or she is the greater of (A) 21 years
of age or (B) the age of legal majority in his or her jurisdiction of residence, and has full power and authority to execute and
deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii)
if a corporation, partnership, or limited liability company or partnership, or association, joint stock company, trust, unincorporated
organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Units, such
entity is duly organized, validly existing and in good standing under the laws of the state of its organization, the consummation
of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its charter or other
organizational documents, such entity has full power and authority to execute and deliver this Agreement and all other related
agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Units, the execution
and delivery of this Agreement has been duly authorized by all necessary action, this Agreement has been duly executed and delivered
on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a
representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this Agreement in
such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability
company or partnership, or other entity for whom the Subscriber is executing this Agreement, and such individual, partnership,
ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform
pursuant to this Agreement and make an investment in the Company, and represents that this Agreement constitutes a legal, valid
and binding obligation of such entity. The execution and delivery of this Agreement will not violate or be in conflict with any
order, judgment, injunction, agreement or controlling document to which the Subscriber is a party or by which it is bound.

 

    	10

    	 

    

 

		e.	The Subscriber understands that the Units are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and such Subscriber’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Subscriber set forth herein in order to determine the availability of such exemptions
and the eligibility of such Subscriber to acquire such securities.

 

		f.	The Subscriber understands that no public market now exists, and there never will be a public market
for, the Units, that a limited public market for the Company’s Common Stock exists and that there can be no assurance that
an active public market for the Common Stock will exist or continue to exist.

 

		g.	The Subscriber, its advisers, if any, and its designated representatives, if any, have received
and reviewed information about the Company, including all Disclosure Materials, and have had an opportunity to discuss the Company’s
business, management and financial affairs with its management. The Subscriber understands that such discussions, as well as any
Disclosure Material provided by the Company, were intended to describe the aspects of the Company’s business and prospects
which the Company believes to be material, but were not necessarily a thorough or exhaustive description, and except as expressly
set forth in this Agreement, the Company makes no representation or warranty with respect to the completeness of such information
and makes no representation or warranty of any kind with respect to any information provided by any entity other than the Company.
Some of such information may include projections as to the future performance of the Company, which projections may not be realized,
may be based on assumptions which may not be correct and may be subject to numerous factors beyond the Company’s control.
Additionally, the Subscriber understands and represents that it is purchasing the Units notwithstanding the fact that the Company
may disclose in the future certain material information the Subscriber has not received, including (without limitation) financial
statements of the Company and or Ekso for the current or prior fiscal periods, and any subsequent period financial statements that
will be filed with the Securities and Exchange Commission, that it is not relying on any such information in connection with its
purchase of the Units and that it waives any right of action with respect to the nondisclosure to it prior to its purchase of the
Units of any such information. Each Subscriber has sought such accounting, legal and tax advice as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Units.

 

		h.	As of the Closing, all actions on the part of Subscriber, and its officers, directors and partners,
if applicable, necessary for the authorization, execution and delivery of this Agreement and the Registration Rights Agreement
and the performance of all obligations of the Subscriber hereunder and thereunder shall have been taken, and this Agreement and
the Registration Rights Agreement, assuming due execution by the parties hereto and thereto, constitute valid and legally binding
obligations of the Subscriber, enforceable in accordance with their respective terms, subject to: (i) judicial principles limiting
the availability of specific performance, injunctive relief, and other equitable remedies and (ii) bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights.

 

    	11

    	 

    

 

		i.	Subscriber represents that neither it nor, to its knowledge, any person or entity controlling,
controlled by or under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf
the Subscriber is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the
United States (Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support
Terrorism); (ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign
Assets Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a
senior non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited
from investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations,
rules or orders (categories (i) through (v), each a “Prohibited Subscriber”). The Subscriber agrees to
provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply
with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. The Subscriber
consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its affiliates and agents of such
information about the Subscriber as the Company reasonably deems necessary or appropriate to comply with applicable U.S. antimony
laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Subscriber is a financial institution
that is subject to the USA Patriot Act, the Subscriber represents that it has met all of its obligations under the USA Patriot
Act. The Subscriber acknowledges that if, following its investment in the Company, the Company reasonably believes that the Subscriber
is a Prohibited Subscriber or is otherwise engaged in suspicious activity or refuses to promptly provide information that the Company
requests, the Company has the right or may be obligated to prohibit additional investments, segregate the assets constituting the
investment in accordance with applicable regulations or immediately require the Subscriber to transfer the Shares, Warrants and/or
the Warrant Shares. The Subscriber further acknowledges that the Subscriber will have no claim against the Company or any of its
affiliates or agents for any form of damages as a result of any of the foregoing actions.

 

			If the Subscriber is affiliated with a non-U.S. banking institution (a “Foreign Bank”),
or if the Subscriber receives deposits from, makes payments on behalf of, or handles other financial transactions related to a
Foreign Bank, the Subscriber represents and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than
solely an electronic address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign
Bank maintains operating records related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking
authority that licensed the Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services
to any other Foreign Bank that does not have a physical presence in any country and that is not a regulated affiliate.

 

		j.	The Subscriber or its duly authorized representative realizes that because of the inherently speculative
nature of businesses of the kind conducted and contemplated by the Company, the Company’s financial results may be expected
to fluctuate from month to month and from period to period and will, generally, involve a high degree of financial and market risk
that could result in substantial or, at times, even total losses for investors in securities of the Company.

 

    	12

    	 

    

 

		k.	The Subscriber has adequate means of providing for its current and anticipated financial needs
and contingencies, is able to bear the economic risk for an indefinite period of time and has no need for liquidity of the investment
in the Units and could afford complete loss of such investment.

 

		l.	The Subscriber is not subscribing for Units as a result of or subsequent to any advertisement,
article, notice or other communication, published in any newspaper, magazine or similar media or broadcast over television, radio,
or the internet, or presented at any seminar or meeting, or any solicitation of a subscription by a person not previously known
to the Subscriber in connection with investments in securities generally.

 

		m.	The Subscriber acknowledges that U.S. federal or state agency or any other government or governmental
agency has passed upon the Units, the Shares, the Warrants or the Warrant Shares or made any finding or determination as to the
fairness, suitability or wisdom of any investments therein.

 

		n.	The Subscriber agrees to be bound by all of the terms and conditions of the Registration Rights
Agreement and to perform all obligations thereby imposed upon it.

 

		o.	All of the information that the Subscriber has heretofore furnished or which is set forth herein
is correct and complete as of the date of this Agreement, and, if there should be any material change in such information prior
to the admission of the undersigned to the Company, the Subscriber will immediately furnish revised or corrected information to
the Company.

 

		p.	(For ERISA plans only) The fiduciary of the ERISA plan (the “Plan”)
represents that such fiduciary has been informed of and understands the Company’s investment objectives, policies and strategies,
and that the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with
the provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Subscriber
fiduciary or Plan (a) is responsible for the decision to invest in the Company; (b) is independent of the Company or any of its
affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Purchaser fiduciary or Plan
has not relied primarily on any advice or recommendation of the Company or any of its affiliates.

 

		6.	Transfer Restrictions. The Subscriber acknowledges and agrees as follows:

 

		a.	The Units, the Shares, the Warrants and the Warrant Shares have not been registered for sale under
the Securities Act, in reliance on the private offering exemption in Section 4(2) thereof; the Company does not currently intend
to register the Units, the Shares, the Warrants or the Warrant Shares under the Securities Act at any time in the future; and the
undersigned will not immediately be entitled to the benefits of Rule 144 with respect to the Units, the Shares, the Warrants and
the Warrant Shares.

 

		b.	The Subscriber understands that there are substantial restrictions on the transferability of the
Shares, the Warrants and the Warrant Shares (collectively, the “Securities”) that the certificates representing
the Securities shall bear a restrictive legend in substantially the following form (or in the case of the Warrants, as shown on
the form of Warrant attached hereto) (and a stop-transfer order may be placed against transfer of such certificates or other instruments):

 

    	13

    	 

    

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED,
ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT
AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION
OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY
BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. HEDGING
TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

The legend
set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of the Securities
upon which it is stamped, if (a) such Shares are sold pursuant to a registration statement under the Securities Act, or (b) such
holder delivers to the Company an opinion of counsel, reasonably acceptable to the Company, that a disposition of the Securities
is being made pursuant to an exemption from such registration and that the Securities, after such transfer, shall no longer be
“restricted securities” within the meaning of Rule 144.

 

		c.	Each Subscriber understands that prior to the Merger, the Company will be a “shell company”
as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and that upon the filing of a Current Report on Form 8-K reporting the consummation of the Merger and the Transactions and otherwise
containing Form 10 information discussed below, the Company will cease to be a shell company. Pursuant to Rule 144(i), securities
issued by a current or former shell company (that is, the Securities) that otherwise meet the holding period and other requirements
of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after the Company (a) is no longer a shell company;
and (b) has filed current “Form 10 information“ (as defined in Rule 144(i)) with the SEC reflecting that it is no longer
a shell company, and provided that at the time of a proposed sale pursuant to Rule 144, the Company is subject to the reporting
requirements of Section 13 or 15(d) of the Exchange Act and has filed all reports and other materials required to be filed by Section
13 or 15(d) of the Exchange Act, as applicable, during the preceding 12 months (or for such shorter period that the issuer was
required to file such reports and materials), other than Form 8-K reports. As a result, the restrictive legends on certificates
for the Securities cannot be removed except in connection with an actual sale meeting the foregoing requirements or pursuant to
an effective registration statement.

 

		7.	Indemnification. The Subscriber agrees to indemnify and hold harmless the Company, the Placement
Agents and any other broker, agent or finder engaged by the Company for the Offering, and their respective officers, directors,
employees, agents, control persons and affiliates from and against all losses, liabilities, claims, damages, costs, fees and expenses
whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation
commenced or threatened) based upon or arising out of the Subscriber’s actual or alleged false acknowledgment, representation
or warranty, or misrepresentation or omission to state a material fact, or breach by the Subscriber of any covenant or agreement
made by the Subscriber, contained herein or in any other document delivered by the Subscriber in connection with this Agreement.

 

    	14

    	 

    

 

		8.	Revocability; Binding Effect. The subscription hereunder may be revoked prior to the Closing
thereon, provided that written notice of revocation is sent and is received by the Company or the Placement Agent at least three
business days prior to the Closing on such subscription. The Subscriber hereby acknowledges and agrees that this Agreement shall
survive the death or disability of the Subscriber and shall be binding upon and inure to the benefit of the parties and their heirs,
executors, administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one person,
the obligations of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties and acknowledgments
herein shall be deemed to be made by and be binding upon each such person and such person’s heirs, executors, administrators,
successors, legal representatives and permitted assigns.

 

		9.	Modification. This Agreement shall not be modified or waived except by an instrument in
writing signed by the party against whom any such modification or waiver is sought to be enforced.

 

		10.	Immaterial Modifications to the Registration Rights Agreement. The Company may, at any time
prior to the initial Closing, amend the Registration Rights Agreement if necessary to clarify any provision therein, without first
providing notice or obtaining prior consent of the Subscriber.

 

		11.	Notices. Any notice or other communication required or permitted to be given hereunder shall
be in writing and shall be mailed by certified mail, return receipt requested, or delivered against receipt to the party to whom
it is to be given (a) if to the Company, at the address set forth above, with a copy to Gottbetter & Partners, LLP, 488 Madison
Ave., 12th Fl., New York, NY 10022, Attention: Adam S. Gottbetter, Esq., facsimile +1-212-400-6901, or (b) if to the Subscriber,
at the address set forth on the Omnibus Signature Page hereof (or, in either case, to such other address as the party shall have
furnished in writing in accordance with the provisions of this Section). Any notice or other communication given by certified mail
shall be deemed given at the time of certification thereof, except for a notice changing a party’s address which shall be
deemed given at the time of receipt thereof.

 

		12.	Assignability. This Agreement and the rights, interests and obligations hereunder are not
transferable or assignable by the Subscriber, and the transfer or assignment of the Units, the Shares, the Warrants or the Warrant
Shares shall be made only in accordance with all applicable laws.

 

		13.	Applicable Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of New York, without reference to the principles thereof relating to the conflict of laws.

 

		14.	Submission to Jurisdiction; Waiver of Trial by Jury. Each
party to this Agreement (a) submits to the exclusive jurisdiction of any state or federal court located in New York County in the
State of New York having subject matter jurisdiction in any action or proceeding arising out of or relating to this Agreement,
(b) agrees that any dispute or controversy concerning, arising out of or relating to this Agreement may be heard and determined
in any such court, and (c) shall not bring any action or proceeding concerning, arising out of or relating to this Agreement in
any other court. Each party to this Agreement waives any defense of inconvenient forum to the maintenance of any action or proceeding
so brought. Any party to this Agreement may make service on another party hereto by sending or delivering a copy of the process
to the party to be served at the address and in the manner provided for the giving of notices in this Agreement. Nothing in this
Section, however, shall affect the right of any party to serve legal process in any other manner permitted by law. EACH PARTY
TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    	15

    	 

    

 

		15.	Blue Sky Qualification. The purchase of Units under this Agreement is expressly conditioned
upon the exemption from qualification of the offer and sale of the Units from applicable federal and state securities laws. The
Company shall not be required to qualify this transaction under the securities laws of any jurisdiction and, should qualification
be necessary, the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted,
in the jurisdiction.

 

		16.	Use of Pronouns. All pronouns and any variations thereof used herein shall be deemed to
refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons referred to may require.

 

		17.	Confidentiality. The Subscriber acknowledges and agrees that any information or data the
Subscriber has acquired from or about the Company or may acquire in the future, not otherwise properly in the public domain, including,
without limitation, the Disclosure Materials, was received in confidence. The Subscriber agrees not to divulge, communicate or
disclose, except as may be required by law or for the performance of this Agreement, or use to the detriment of the Company or
for the benefit of any other person, or misuse in any way, any confidential information of the Company, including any scientific,
technical, trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated
by the Company as confidential or proprietary, including, but not limited to, internal personnel and financial information of the
Company or its affiliates, the manner and methods of conducting the business of the Company or its affiliates and confidential
information obtained by or given to the Company about or belonging to third parties. The Subscriber understands that the Company
may rely on Subscriber’s agreement of confidentiality to comply with the exemptive provisions of Regulation FD under the
Securities Act of 1933 as set forth in Rule 100(a)(b)(2)(ii) of Regulation FD. In addition, the Subscriber acknowledges that it
is aware that the United States securities laws generally prohibit any person who is in possession of material nonpublic information
about a public company such as the Company from purchasing or selling securities of such company.

 

		18.	Anti-Dilution. The Shares shall have anti-dilution protection such that if within twenty-four
(24) months after the final Closing of the Offering the Company shall issue Additional Shares of Common Stock (as defined below)
without consideration or for a consideration per share, or with an exercise or conversion price per share, less than the Purchase
Price, the Subscriber shall be entitled to receive from the Company (for no additional consideration) additional Shares in an amount
such that, when added to the number of Shares purchased by Subscriber under this Agreement, will equal the number of Shares that
the Subscriber’s Purchase Price for the Shares set forth on the Subscriber’s signature page hereof would have purchased
at the Adjusted Price (as defined below). The “Adjusted Price” shall be a price (calculated to the nearest
cent) determined by multiplying the Adjusted Price per share in effect immediately prior to such issue (which, for avoidance of
doubt, shall be $1.00 prior to the first such issue) by a fraction, (A) the numerator of which shall be (1) the number of shares
of Common Stock outstanding immediately prior to such issue plus (2) the number of shares of Common Stock which the aggregate consideration
received or to be received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at
such Adjusted Price; and (B) the denominator of which shall be (1) the number of shares of Common Stock outstanding immediately
prior to such issue plus (2) the number of such Additional Shares of Common Stock so issued; provided that, (i) for the
purpose of this Section, all shares of Common Stock issuable upon conversion or exchange of convertible securities outstanding
immediately prior to such issue shall be deemed to be outstanding, and (ii) the number of shares of Common Stock deemed issuable
upon conversion or exchange of such outstanding convertible securities shall be determined without giving effect to any adjustments
to the conversion or exchange price or conversion or exchange rate of such convertible securities resulting from the issuance of
Additional Shares of Common Stock that is the subject of this calculation.

 

    	16

    	 

    

 

“Additional
Shares of Common Stock” shall mean all shares of Common Stock issued by the Company after the first Closing of the
Offering (including without limitation any shares of Common Stock issuable upon conversion or exchange of any convertible securities
or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of Common Stock issued or issuable
upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding as of immediately
following the Merger and the first Closing; (ii) shares of Common Stock issued or issuable upon conversion of the Warrants, the
Bridge Warrants, the Placement Agent Warrants or the Bridge Placement Agent Warrants; (iii) shares of Common Stock issued or issuable
by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock relating to any recapitalization,
reclassification or reorganization of the capital stock of the Company, or any consolidation or merger of the Company with another
corporation, or the sale of all or substantially all of its assets or other transaction effected in such a way that there is no
change of control of the Company; (iv) shares of Common Stock (or options with respect thereto) issued or issuable to employees
or directors of, or consultants to, the Company or any of its Subsidiaries pursuant to a plan, agreement or arrangement approved
by the Board of Directors of the Company, including but not limited to, the Company’s equity incentive plan; (v) shares of
Common Stock issued or issuable pursuant to the acquisition of another entity or business by the Company by merger, purchase of
substantially all of the assets or other reorganization or pursuant to a joint venture agreement, but not including a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business
is investing in securities; and (v) securities issued to financial institutions, institutional investors or lessors in connection
with credit arrangements, equipment financings, lease arrangements or similar transactions, in each case approved by a majority
of disinterested directors of the Company, and in the aggregate not exceeding ten percent (10%) of number of shares of Common Stock
outstanding at any time.

 

		19.	Miscellaneous.

 

		a.	This Agreement, together with the Registration Rights Agreement and the Warrant, constitute the
entire agreement between the Subscriber and the Company with respect to the Offering and supersede all prior oral or written agreements
and understandings, if any, relating to the subject matter hereof. The terms and provisions of this Agreement may be waived, or
consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such
terms or provisions.

 

		b.	The representations and warranties of the Company and the Subscriber made in this Agreement shall
survive the execution and delivery hereof and delivery of the Common Stock and the Warrants contained in the Units
for a period of twelve (12) months following the Closing Date.

 

    	17

    	 

    

 

		c.	Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys,
accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby,
whether or not the transactions contemplated hereby are consummated.

 

		d.	This Agreement may be executed in one or more original or facsimile counterparts, each of which
shall be deemed an original, but all of which shall together constitute one and the same instrument and which shall be enforceable
against the parties actually executing such counterparts. The exchange of copies of this Agreement and of signature pages by facsimile
transmission or in .pdf format shall constitute effective execution and delivery of this Agreement as to the parties and may be
used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile or in pdf format shall
be deemed to be their original signatures for all purposes.

 

		e.	Each provision of this Agreement shall be considered separable and, if for any reason any provision
or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair
the operation of or affect the remaining portions of this Agreement.

 

		f.	Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of
this Agreement as set forth in the text.

 

		g.	The Subscriber understands and acknowledges that there may be multiple Closings for the Offering.

 

		h.	The Subscriber hereby agrees to furnish the Company such other information as the Company may request
prior to the Closing with respect to its subscription hereunder.

 

		20.	Omnibus Signature Page. This Agreement is intended to be read and construed in conjunction
with the Registration Rights Agreement. Accordingly, pursuant to the terms and conditions of this Agreement and the Registration
Rights Agreement, it is hereby agreed that the execution by the Subscriber of this Agreement, in the place set forth on the Omnibus
Signature Page below, shall constitute agreement to be bound by the terms and conditions hereof and the terms and conditions of
the Registration Rights Agreement, with the same effect as if each of such separate but related agreement were separately signed.

 

		21.	Public Disclosure. Neither the Subscriber nor any officer, manager, director, member, partner,
stockholder, employee, affiliate, affiliated person or entity of the Subscriber shall make or issue any press releases or otherwise
make any public statements or make any disclosures to any third person or entity with respect to the transactions contemplated
herein and will not make or issue any press releases or otherwise make any public statements of any nature whatsoever with respect
to the Company without the Company’s express prior approval. The Company has the right to withhold such approval in its sole
discretion.

 

		22.	Potential Conflicts.Adam S. Gottbetter is
the owner of Gottbetter Capital Group, Inc., Gottbetter & Partners, LLP, and the Placement Agent.  Gottbetter Capital
Group or another affiliate of Mr. Gottbetter may now or hereafter own shares of the Company.  Gottbetter &
Partners, LLP, is counsel to the Company and has represented the Company in the proposed transaction, for which it will receive
legal fees in accordance with an executed retainer agreement.  The Placement Agent will receive a fee and warrants as
described above pursuant to an executed agreement.

 

    	18

    	 

    

 

EKSO BIONICS HOLDINGS, INC.

 

IN WITNESS WHEREOF, the Company has duly executed this Subscription
Agreement as of the 15th day of January, 2014.

 

	 	EKSO BIONICS HOLDINGS, INC.
	 	 	 
	 	By:	/s/ Pedro Perez Niklitschek
	 	Name:	Pedro Perez Niklitschek
	 	Title:	Chief Executive Officer

 

    	19

    	 

    

 

How to subscribe for Units in the private
offering of

PN
Med Group Inc.  (intended
to be renamed Ekso Bionics Holdings, Inc.):

 

		1.	Date and Fill in the number of Units being purchased and complete and sign the Omnibus
Signature Page.

 

		2.	Initial the Investor Certification in the appropriate place or places.

 

		3.	Complete and sign the Investor Profile.

 

		4.	Complete and sign the Anti-Money Laundering Information Form.

 

		5.	Fax or email all forms and then send all signed original documents to:

 

Gottbetter & Partners, LLP

488 Madison Avenue, 12th Floor

New York, NY  10022

Facsimile Number:  (212)
400-6901

Telephone Number:  (212)
400-6900

Attn:  Camille Maiorano-Ortiz

E-mail Address:  cmo@gottbetter.com

 

		6.	If you are paying the Purchase Price by check, a [certified or other bank] check
for the exact dollar amount of the Purchase Price for the number of Units you are purchasing should be made payable to the order
of “CSC Trust Company of Delaware, as Escrow Agent for PN MED GROUP INC., ACCT #79-2033” and should be sent
directly to CSC Trust Company of Delaware, 2711 Centerville Road, One Little Falls Centre, Wilmington, DE 19808, Attn: Alan
R. Halpern.

 

		7.	If you are paying the Purchase Price by wire transfer, you should send a wire transfer
for the exact dollar amount of the Purchase Price for the number of Units you are purchasing according to the following instructions:

 

 

	Bank:	
        PNC Bank

        300 Delaware Avenue

        Wilmington, DE 19899

	ABA Routing #:	031100089
	SWIFT CODE:	PNCCUS33
	Account Name:	CSC Trust Company of Delaware
	Account #:	5605012373
	Reference:	“FFC: PN Med Group Inc. Escrow; 79-2033 – [insert Subscriber’s name]”
	CSC Contact:	Alan R. Halpern

 

Thank you for your interest,

 

PN Med Group Inc.

 

    	 

    	 

    

 

PN
MED GROUP INC.  (intended
to be renamed EKSO BIONICS HOLDINGS, INC.)

OMNIBUS SIGNATURE PAGE TO

SUBSCRIPTION AGREEMENT AND REGISTRATION
RIGHTS AGREEMENT

 

The undersigned, desiring to: (i) enter
into the Subscription Agreement, dated as of ____________ ___,1 2013 (the “Subscription Agreement”),
between the undersigned, PN Med Group Inc., a Nevada corporation (the “Company”),
and the other parties thereto, in or substantially in the form furnished to the undersigned, (ii) enter into the Registration Rights
Agreement (the “Registration Rights Agreement”), among the undersigned, the
Company and the other parties thereto, in or substantially in the form furnished to the undersigned and (iii) purchase the Units
of the Company’s securities as set forth in the Subscription Agreement and below, hereby agrees to purchase such Units from
the Company and further agrees to join the Subscription Agreement and the Registration Rights Agreement as a party thereto, with
all the rights and privileges appertaining thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned
specifically acknowledges having read the representations section in the Securities Purchase Agreement entitled “Representations
and Warranties of the Subscriber” and hereby represents that the statements contained therein are complete and accurate with
respect to the undersigned as a Subscriber.

 

IN WITNESS WHEREOF, the Subscriber hereby
executes this Subscription Agreement and the Registration Rights Agreement.

 

Dated: _______________________, 2014

 

	 	X	$1.00                   	=	$                                         
	Number of Units	 	Purchase Price per Unit	 	Total Purchase Price

 

	SUBSCRIBER (individual)	             	SUBSCRIBER (entity)
	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 	 
	 	 	 
	Print Name	 	Signature
	 	 	 
	 	 	Print Name:	 
	Signature (if Joint Tenants or Tenants in Common)	Title:	 
	 	 	 
	Address of Principal Residence:	 	Address of Executive Offices:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number(s):	 	IRS Tax Identification Number:
	 	 	 
	 	 	 
	Telephone Number:	 	Telephone Number:
	 	 	 
	 	 	 
	Facsimile Number:	 	Facsimile Number:
	 	 	 
	 	 	 
	E-mail Address:	 	E-mail Address:
	 	 	 

 

1 Will
reflect the Closing Date. Not to be completed by Subscriber.

 

    	21

    	 

    

 

PN
MED GROUP INC. (intended
to be renamed EKSO BIONICS HOLDINGS, INC.)

ACCREDITED INVESTOR CERTIFICATION

 

For Individual Investors Only

(all Individual Investors must INITIAL
where appropriate):

 

	Initial _______	I have a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating your net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability.)
	 	 
	Initial _______	I have had an annual gross income for the past two years of at least US$200,000 (or US$300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 
	Initial _______	I am a director or executive officer of Ekso Bionics, Inc.

 

For Non-Individual
Investors (Entities)

(all Non-Individual
Investors must INITIAL where appropriate):

 

	Initial _______	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above. 
	 	 
	Initial _______	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least US$5 million and was not formed for the purpose of investing the Company.
	 	 
	Initial _______	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment advisor.
	 	 
	Initial _______	The investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
	 	 
	Initial _______	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet at least one of the criteria for Individual Investors.
	 	 
	Initial _______	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 
	Initial _______	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 
	Initial _______	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding US$5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 
	Initial _______	The investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.
	 	 
	Initial _______	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of US$5,000,000.
	 	 
	Initial _______	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act of 1933, or a registered investment company.

 

    	 

    	 

    

 

PN
MED GROUP INC.  (intended
to be renamed EKSO BIONICS HOLDINGS, INC.)

Investor Profile

(Must be completed by Investor)

 

Section A - Personal Investor Information

 

	Investor Name(s):	 

 

	Individual executing Profile or Trustee:	 

 

	Social Security Numbers / Federal I.D. Number:	 

 

	Date of Birth:	 	 	Marital Status:	 

	Joint Party Date of Birth:	 	 	Investment Experience (Years):	 

	Annual Income:	 	 	Liquid Net Worth:	 
	Net Worth*:	 	 	 	 
	 	 	 	 	 
	Tax Bracket:	_____ 15% or below                  _____ 25% - 27.5%                  _____
Over 27.5%

 

	Home Street Address:	 

 

	Home City, State & Zip Code:	 

 

	Home Phone:	 	  Home Fax:	 	  Home Email:	 

 

	Employer:  	 

 

	Employer Street Address:	 

 

	Employer City, State & Zip Code:	 

 

	Bus. Phone:	 	  Bus. Fax:	 	  Bus. Email:	 

 

	Type of Business:	 

 

	Outside Broker/Dealer:	 

 

Section B – Certificate Delivery
Instructions

 

____ Please deliver certificate to the Employer Address listed
in Section A.

____ Please deliver certificate to the Home Address listed in
Section A.

____ Please deliver certificate to the following address: ________________________________________

 

Section C – Form of Payment
– Check or Wire Transfer

 

____ Check payable to CSC Trust Company
of Delaware, as Escrow Agent for PN Med Group Inc.

____ Wire funds from my outside account
according to Section 1(a) of the Securities Purchase Agreement.

____ The funds for this investment
are rolled over, tax deferred from __________ within the allowed 60 day window.

 

Please check if you are a FINRA member
or affiliate of a FINRA member firm: ____

 

	 	 	 
	Investor Signature	 	Date

 

		*	For purposes of calculating your net worth in this form, (a) your primary residence shall
not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value of your
primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount
of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding 60 days before such
time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability);
and (c) indebtedness that is secured by your primary residence in excess of the estimated fair market value of your primary residence
at the time of your purchase of the securities shall be included as a liability. 

 

    	 

    	 

    

 

ANTI MONEY LAUNDERING REQUIREMENTS

 

The USA PATRIOT Act

 

The USA PATRIOT Act is designed to detect,
deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage
firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money
laundering programs.

 

To help you understand these efforts, we
want to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.

 

What is money laundering?

 

Money laundering is the process of disguising
illegally obtained money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection
with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.

 

How big is the problem and why is it
important?

 

The use of the U.S. financial system by
criminals to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department,
one recent estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

 

What are we required to do to eliminate
money laundering?

 

Under rules required by the USA PATRIOT
Act, our anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent
audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with such laws.
As part of our required program, we may ask you to provide various identification documents or other information. Until you provide
the information or documents we need, we may not be able to effect any transactions for you.

 

    	 

    	 

    

 

ANTI-MONEY
LAUNDERING INFORMATION FORM

The following is required in accordance
with the AML provision of the USA PATRIOT ACT.

(Please fill out and return with requested
documentation.)

	INVESTOR NAME:	 	 
	 	 	 
	LEGAL ADDRESS:	 	 
	 	 	 
	 	 	 
	 	 	 
	SSN# or TAX ID#	 	 
	OF INVESTOR:	 	 
	 	 	 
	YEARLY INCOME: 	 	 
	 	 	 
	NET WORTH: 	 	*

 

* For purposes of calculating your net
worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary
residence, up to the estimated fair market value of your primary residence at the time of your purchase of the securities, shall
not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the
securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of your primary residence,
the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in
excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall be included
as a liability. 

 

	INVESTMENT OBJECTIVE(S):	 

 

	ADDRESS OF BUSINESS OR OF EMPLOYER: 	 
	 	 
	 	 

 

	FOR INVESTORS WHO ARE INDIVIDUALS:  AGE: 	 

 

	FOR INVESTORS WHO ARE INDIVIDUALS:  OCCUPATION:  	 

 

	FOR INVESTORS WHO ARE ENTITIES:  TYPE OF BUSINESS: 	 

 

IDENTIFICATION & DOCUMENTATION
AND SOURCE OF FUNDS:

 

		1.	Please submit a copy of non-expired identification for the authorized signatory(ies) on the investment
documents, showing name, date of birth, address and signature. The address shown on the identification document MUST match the
Investor’s address shown on the Investor Signature Page.

 

	Current Driver’s License	or	Valid Passport	or	Identity Card

(Circle one or more)

		2.	If the Investor is a corporation, limited liability company, trust or other type of entity, please
submit the following requisite documents: (i) Articles of Incorporation, By-Laws, Certificate of Formation, Operating Agreement,
Trust or other similar documents for the type of entity; and (ii) Corporate Resolution or power of attorney or other similar document
granting authority to signatory(ies) and designating that they are permitted to make the proposed investment.

 

		3.	Please advise where the funds were derived from to make the proposed investment:

 

	Investments	Savings	Proceeds of Sale	Other ____________

(Circle one or more)

	Signature:	 	 
	 	 	 
	Print Name:	 	 
	 	 	 
	Title (if applicable):	 	 
	 	 	 
	Date:Exhibit 10.6

 

Warrant Certificate No. ______

 

NEITHER THE SECURITIES REPRESENTED HEREBY
NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED
OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE, AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS, PRIOR
TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY
TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

 

	Effective Date: _________, 2014	Expiration
Date: __________, 2017

 

EKSO BIONICS HOLDINGS, INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

Ekso Bionics Holdings, Inc.,
a Nevada corporation (the “Company”), for value received on the Effective Date, hereby issues to __________________________
(the “Holder”) this Warrant (the “Warrant”) to purchase ______________ shares (as from time
to time adjusted as hereinafter provided) (each such share a “Warrant Share” and all such shares being the “Warrant
Shares”) of the Company’s Common Stock (as defined below), at the Exercise Price (as defined below), as adjusted
from time to time as provided herein, on or before the Expiration Date, all subject to the following terms and conditions.

 

This Warrant is one
of a series of Warrants of like tenor being issued to holders of the 10% senior subordinated secured convertible promissory notes
(the “Bridge Notes”) of Ekso Bionics, Inc., in connection with the Company’s private offering (the
“Offering”) of the Bridge Notes in accordance with, and subject to, the terms and conditions described in the
Securities Purchase Agreement entered into by and between the Company and buyer(s) of the Notes set forth on the signature pages
affixed thereto (the “Purchase Agreement”). Capitalized terms used herein without definition have the meanings
ascribed to them in the Purchase Agreement.

 

    	 

    	 

    

 

As used in this
Warrant, (i) “Business Day” means any day other than Saturday, Sunday or any other day on which commercial
banks in the City of New York, New York, are authorized or required by law or executive order to close; (ii) “Common
Stock” means the common stock of the Company, $0.001 par value per share, including any securities issued or
issuable with respect thereto or into which or for which such shares may be exchanged for, or converted into, pursuant to any
stock dividend, stock split, stock combination, recapitalization, reclassification, reorganization or other similar event;
(iii) “Exercise Price” means $1.00 per share of Common Stock, subject to adjustment as provided
herein; (iv) “Trading Day” means any day on which the Common Stock is traded on the primary national or
regional stock exchange on which the Common Stock is listed, or if not so listed, the OTC Bulletin Board or the OTC Markets,
if quoted thereon, is open for the transaction of business; and (v)
“Affiliate” means any person that, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with, a person, as such terms are used and construed in Rule 144 promulgated
under the Securities Act of 1933, as amended (the “Securities Act”).

 

1.           DURATION
AND EXERCISE OF WARRANTS

 

(a)          Exercise
Period. The Holder may exercise this Warrant in whole or in part on any Business Day on or before 5:00 P.M., Eastern Time,
on the Expiration Date, at which time this Warrant shall become void and of no value.

 

(b)          Exercise
Procedures.

 

(i)          While
this Warrant remains outstanding and exercisable in accordance with Section 1(a), the Holder may exercise this Warrant in whole
or in part at any time and from time to time by:

 

(A)         delivery
to the Company of a duly completed and executed copy of the notice of exercise attached as Exhibit A (the “Notice
of Exercise”);

 

(B)         surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify
in writing to the Holder; and

 

(C)         payment
of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, the “Aggregate Exercise Price”) made in the form of cash, or by certified check, wire
transfer, bank draft or money order payable in lawful money of the United States of America.

 

(ii)         Upon
the exercise of this Warrant in compliance with the provisions of this Section 1(b), and except as limited pursuant to Section
1(b)(iii), the Company shall promptly issue and cause to be delivered to the Holder a certificate for the Warrant Shares purchased
by the Holder. Each exercise of this Warrant shall be effective immediately prior to the close of business on the date (the “Date
of Exercise”) that the conditions set forth in Section 1(b) have been satisfied, as the case may be. Upon delivery of
each of the items set forth in Section 1(b)(i), the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of
the certificates evidencing such Warrant Shares.

 

    	2

    	 

    

 

(iii)        Notwithstanding
the foregoing provisions of this Section 1(b), the Holder may not exercise this Warrant if and to the extent that such exercise
would require the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common
Stock, less all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible
into shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to permit the Holder
to exercise this Warrant, then the Company shall use commercially reasonable efforts to obtain the necessary stockholder consent
to increase the authorized number of shares of Common Stock to permit such Holder to exercise this Warrant pursuant to Section
1(b)(i).

 

(c)          Partial
Exercise. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the number of Warrant
Shares referenced by this Warrant; provided, that any such partial exercise must be for an integral number of Warrant Shares. If
this Warrant is exercised in part, the Company shall issue, at its expense, a new Warrant, in substantially the form of this Warrant,
referencing such reduced number of Warrant Shares that remain subject to this Warrant.

 

(e)          Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with Section 15.

 

2.           ISSUANCE
OF WARRANT SHARES

 

(a)          The
Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.

 

(b)          The
Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record holder
of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner thereof
for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.

 

(c)          The
Company will not, by amendment of its articles of incorporation, by-laws or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying
out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to protect the rights
of the Holder to exercise this Warrant, or against impairment of such rights.

 

    	3

    	 

    

 

3.           ADJUSTMENTS
OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES

 

(a)          The
Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time
to time upon the occurrence of certain events described in this Section 3(a); provided, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less all
amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into shares
of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common Stock.
If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment, the
Company shall use its commercially reasonable efforts to obtain the necessary stockholder consent to increase the authorized number
of shares of Common Stock to make such an adjustment pursuant to this Section 3(a).

 

(i)          Subdivision
or Combination of Stock. In case the Company shall at any time subdivide (whether by way of stock dividend, stock split or
otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior
to such subdivision shall be proportionately reduced and the number of Warrant Shares shall be proportionately increased, and conversely,
in case the outstanding shares of Common Stock of the Company shall be combined (whether by way of stock combination, reverse stock
split or otherwise) into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Shares shall be proportionately decreased. The Exercise Price and the Warrant
Shares, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in
this Section 3(a)(i).

 

(ii)         Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, the holders of Common Stock (or any shares of stock
or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,
without payment therefore:

 

(A)         any
shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common Stock,
or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
or

 

(B)         additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section 3(a)(i) above),

 

    	4

    	 

    

 

then and in each such case, the Exercise
Price and the number of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted proportionately, and the
Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock
receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and
property (including cash in the cases referred to above) that such Holder would hold on the date of such exercise had such Holder
been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive
such shares or all other additional stock and other securities and property. The Exercise Price and the Warrant Shares, as so adjusted,
shall be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii).

 

(iii)        Reorganization,
Reclassification, Consolidation, Merger or Sale. If any recapitalization, reclassification or reorganization of the capital
stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially
all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be entitled to receive
stock, securities or other assets or property (an “Organic Change”), then lawful and adequate provisions shall
be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares
of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented
by this Warrant) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in
exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore
purchasable and receivable assuming the full exercise of the rights represented by this Warrant. In the event of any Organic Change,
appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the
end that the provisions hereof (including, without limitation, provisions for adjustments of the Exercise Price and of the number
of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares
of stock, securities or assets thereafter deliverable upon the exercise hereof. To the extent necessary to effect the foregoing
provisions, the successor corporation (if other than the Company) resulting from such consolidation or merger or the corporation
purchasing such assets shall assume by written instrument reasonably satisfactory in form and substance to the Holder executed
and mailed or delivered to the registered Holder hereof at the last address of such Holder appearing on the books of the Company,
the obligation to deliver to such Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions,
such Holder may be entitled to purchase. If there is an Organic Change, then the
Company shall cause to be mailed to the Holder at its last address as it shall appear on the books and records of the Company,
at least 10 calendar days before the effective date of the Organic Change, a notice stating the date on which such Organic Change
is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares for securities, cash, or other property delivered upon such Organic Change; provided,
that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. The Holder is entitled to exercise this Warrant during the 10-day period commencing
on the date of such notice to the effective date of the event triggering such notice. In any event, the successor corporation (if
other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall be deemed to
assume such obligation to deliver to such Holder such shares of stock, securities or assets even in the absence of a written instrument
assuming such obligation to the extent such assumption occurs by operation of law.

 

    	5

    	 

    

 

(b)          Adjustment
of Exercise Price upon Issuance of Additional Shares of Common Stock. In the event the Company shall at any time prior to the
Expiration Date issue Additional Shares of Common Stock, as defined below, without consideration or for a consideration per share
less than the Exercise Price in effect immediately prior to such issue, then the Exercise Price shall be reduced, concurrently
with such issue, to a price (calculated to the nearest cent) determined by multiplying such Exercise Price by a fraction, (A) the
numerator of which shall be (1) the number of shares of Common Stock outstanding immediately prior to such issue plus (2) the number
of shares of Common Stock which the aggregate consideration received or to be received by the Company for the total number of Additional
Shares of Common Stock so issued would purchase at such Exercise Price; and (B) the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares of Common Stock so
issued; provided that, (i) for the purpose of this Section 3(b), all shares of Common Stock issuable upon conversion or
exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the
number of shares of Common Stock deemed issuable upon conversion or exchange of such outstanding convertible securities shall be
determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such
convertible securities resulting from the issuance of Additional Shares of Common Stock that is the subject of this calculation.
For purposes of this Warrant, “Additional Shares of Common Stock” shall mean all shares of Common Stock issued
by the Company after the Effective Date (including without limitation any shares of Common Stock issuable upon conversion or exchange
of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares
of Common Stock issued or issuable upon conversion or exchange of any convertible securities or exercise of any options outstanding
on the Effective Date; (ii) shares of Common Stock issued or issuable upon conversion of the warrants issued in connection with
the Offering; (iii) shares of Common Stock issued or issuable by reason of a dividend, stock split, split-up or other distribution
on shares of Common Stock that is covered by Sections 3(a)(i) through 3(a)(iii) above; (iv) shares of Common Stock issued in a
registered public offering under the Securities Act; (v) shares of Common Stock issued or issuable pursuant to the acquisition
of another corporation by the Company by merger, purchase of substantially all of the assets or other reorganization or pursuant
to a joint venture agreement; (vi) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants
to, the Company pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements
approved by the Board of Directors, or upon exercise of options or warrants granted to such parties pursuant to any such plan or
arrangement; (vii) any securities issued or issuable by the Company pursuant to the Purchase Agreement or the PIPE. The provisions
of this Section 3(b) shall not operate to increase the Exercise Price.

 

Upon each adjustment
of the Exercise Price pursuant to the provisions of this Section 3(b), the number of Warrant Shares issuable upon exercise of this
Warrant shall be adjusted by multiplying a number equal to the Exercise Price in effect immediately prior to such adjustment by
the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such adjustment and dividing the product
so obtained by the adjusted Exercise Price.

 

    	6

    	 

    

 

(c)          Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such
adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at the time would
be received upon the exercise of the Warrant.

 

(d)          Certain
Events. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but the lack of
any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the basic intent
and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the Holder under this
Warrant in accordance with the basic intent and principles of such provisions, then the Company's Board of Directors will, in good
faith and subject to applicable law, make an appropriate adjustment to protect the rights of the Holder; provided, that
no such adjustment pursuant to this Section 3(d) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 3.

 

4.           TRANSFERS
AND EXCHANGES OF WARRANT AND WARRANT SHARES

 

(a)          Registration
of Transfers and Exchanges. Subject to Section 4(c), upon the Holder’s surrender of this Warrant, with a duly executed
copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder, the Company shall register the transfer of all or any
portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in substantially the form of
this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in similar form, evidencing the
remaining acquisition rights not transferred, to the Holder requesting the transfer.

 

(b)          Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new Warrant or Warrants, in substantially
the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares, which may then be purchased
hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase such number of
Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions regarding
such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency
as the Company may specify in writing to the Holder.

 

(c)          Restrictions
on Transfers. This Warrant may not be transferred at any time without (i) registration under the Securities Act or (ii) an
exemption from such registration and a written opinion of legal counsel addressed to the Company that the proposed transfer of
the Warrant may be effected without registration under the Securities Act, which opinion will be in form and from counsel reasonably
satisfactory to the Company.

    	7

    	 

    

 

(d)          Permitted
Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 4, the Holder may transfer, with or
without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as such
term is defined under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required by Section
4(c)(ii), provided, that the Holder delivers to the Company and its counsel certification, documentation, and other assurances
reasonably required by the Company’s counsel to enable the Company’s counsel to render an opinion to the Company’s
Transfer Agent that such transfer does not violate applicable securities laws.

 

5.           MUTILATED
OR MISSING WARRANT CERTIFICATE

 

If this Warrant is
mutilated, lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in exchange for and
upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new Warrant, in substantially
the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares; provided, that, as
a prerequisite to the issuance of a substitute Warrant, the Company may require satisfactory evidence of loss, theft or destruction
as well as an indemnity from the Holder of a lost, stolen or destroyed Warrant.

 

6.            PAYMENT
OF TAXES

 

The Company will pay
all transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant and the Warrant Shares
(and replacement Warrants) including, without limitation, all documentary and stamp taxes; provided, however, that
the Company shall not be required to pay any tax in respect of the transfer of this Warrant, or the issuance or delivery of certificates
for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other than to the Holder.

 

7.           FRACTIONAL
WARRANT SHARES

 

No fractional Warrant
Shares shall be issued upon exercise of this Warrant. Upon the full exercise of this Warrant, the Company, in lieu of issuing any
fractional Warrant Share, shall round up the number of Warrant Shares issuable to nearest whole share.

 

8.           NO
STOCK RIGHTS AND LEGEND

 

No holder of this Warrant,
as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that may at any time be issuable
on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, the
rights of a stockholder of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or give or withhold consent to any corporate action or to receive notice of meetings or other actions affecting
stockholders (except as provided herein), or to receive dividends or subscription rights or otherwise (except as provide herein).

 

    	8

    	 

    

 

Each certificate for
Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued to any subsequent
transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form:

 

NEITHER THE SECURITIES REPRESENTED
HEREBY NOR THE SECURITIES ISSUABLE UPON THE CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 UNDER THE SECURITIES ACT, IF AVAILABLE,
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (D) IN A TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS, PRIOR
TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY
TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

  

9.           REGISTRATION
RIGHTS

 

The Holder shall be
entitled to the registration rights with respect to the Warrant Shares set forth in, and subject to the conditions of, the Registration
Rights Agreement.

 

10.         NOTICES

 

All notices, consents,
waivers, and other communications under this Warrant must be in writing and will be deemed given to a party when (a) delivered
to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b) sent by facsimile
or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee, if sent by
certified mail, return receipt requested, if to the registered Holder hereof; or (d) seven days after the placement of the notice
into the mails (first class postage prepaid), to the Holder at the address, facsimile number, or e-mail address furnished by the
registered Holder to the Company in accordance with the Subscription Agreement by and between the Company and the Holder or, if
the registered Holder is not the original purchaser of this Warrant, then as provided in the Form of Assignment delivered to the
Company pursuant to Section 4(a) in connection with the assignment of this Warrant to such Holder, or if to the Company, to it
at:

 

Ekso Bionics Holdings, Inc.

1414 Harbour Way South Suite1201

Richmond, CA 94804

 

    	9

    	 

    

 

Attn:

Facsimile:

 

(or to such other address, facsimile number,
or e-mail address as the Holder or the Company as a party may designate by notice to the other party in accordance with this Section
10) with a copy to

 

Gottbetter
& Partners, LLP

488 Madison
Avenue, 12th Floor

New York,
New York 10022

Facsimile Number: (212) 400-6901

Telephone Number: (212) 400-6900

Attn: Adam S. Gottbetter

E-mail Address:
notices@gottbetter.com

 

11.         SEVERABILITY

 

If a court of competent
jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant will remain in
full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will remain in full force
and effect to the extent not held invalid or unenforceable.

 

12.         BINDING
EFFECT

 

This Warrant shall
be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered Holder or
Holders from time to time of this Warrant and the Warrant Shares.

 

13.         SURVIVAL
OF RIGHTS AND DUTIES

 

This Warrant shall
terminate and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date or the date on
which this Warrant has been exercised in full.

 

14.         GOVERNING
LAW

 

This Warrant will be
governed by and construed under the laws of the State of New York without regard to conflicts of laws principles that would require
the application of any other law.

 

    	10

    	 

    

 

15.         DISPUTE
RESOLUTION

 

In the case of a dispute
as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the
disputed determinations or arithmetic calculations via facsimile within five (5) Business Days of receipt of the Notice of Exercise
giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination
or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall, at its sole discretion, within five (5) Business Days, submit
via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder, or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform
the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from
the time it receives the disputed determinations or calculations; provided that, if such disputed determination or arithmetic calculation
being submitted by the Holder is determined to be incorrect, then the expense of the investment bank or the accountant shall be
the responsibility of the Holder. Such investment bank’s or accountant’s determination or calculation, as the case
may be, shall be final, binding and conclusive upon the parties thereto.

 

16.         NOTICES
OF RECORD DATE

 

Upon (a) any establishment
by the Company of a record date of the holders of any class of securities for the purpose of determining the holders thereof who
are entitled to receive any dividend or other distribution, or right or option to acquire securities of the Company, or any other
right, or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation of the Company with or into
any other corporation, any transfer of all or substantially all the assets of the Company, or any voluntary or involuntary dissolution,
liquidation or winding up of the Company, or the sale, in a single transaction, of a majority of the Company’s voting stock
(whether newly issued, or from treasury, or previously issued and then outstanding, or any combination thereof), the Company shall
mail to the Holder at least ten (10) Business Days, or such longer period as may be required by law, prior to the record date specified
therein, a notice specifying (i) the date established as the record date for the purpose of such dividend, distribution, option
or right and a description of such dividend, option or right, (ii) the date on which any such reorganization, reclassification,
transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected to become effective and (iii) the
date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange their shares of Common Stock
for securities or other property deliverable upon such reorganization, reclassification, transfer, consolation, merger, dissolution,
liquidation or winding up.

 

17.         RESERVATION
OF SHARES

 

The Company shall reserve
and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise of this Warrant, free
from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to time be exercisable. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation. Without limiting the generality of the foregoing, the Company covenants
that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited to consents from the Company’s
stockholders or Board of Directors or any public regulatory body, as may be necessary to enable the Company to perform its obligations
under this Warrant.

 

    	11

    	 

    

 

18.         HEADINGS

 

The headings used in
this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

19.         AMENDMENT
AND WAIVERS

 

Any term of this Warrant
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), with the written consent of the Company and the Holders of a majority of the Warrant Shares
issuable upon exercise of the Warrants.

 

20.         NO
THIRD PARTY RIGHTS

 

This Warrant is not
intended, and will not be construed, to create any rights in any parties other than the Company and the Holder, and no person or
entity may assert any rights as third-party beneficiary hereunder.

 

[SIGNATURE PAGE FOLLOWS]

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed as of the date first set forth above.

 

	 	ESKO BIONICS HOLDINGS, INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	 

    	 

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

(To be executed by the Holder of Warrant
if such Holder desires to exercise Warrant)

 

To EKSO Bionics Holdings, Inc.:

 

The undersigned hereby
irrevocably elects to exercise this Warrant and to purchase thereunder, ___________________ full shares of  EKSO Bionics Holdings, Inc. common
stock issuable upon exercise of the Warrant and delivery of $_________ (in cash as provided for in the foregoing Warrant) and any
applicable taxes payable by the undersigned pursuant to such Warrant.

 

The undersigned
requests that certificates for such shares be issued in the name of:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(Please print name, address and social security
or federal employer

identification number (if applicable))*

 

If the shares issuable
upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire upon the exercise of
the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered
to:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(Please print name, address and social security
or federal employer

identification number (if applicable))*

 

	 	Name of Holder (print):       ________________________
	 	(Signature):   ___________________________________
	 	(By:)  _________________________________________
	 	(Title:) ________________________________________
	 	Dated:   ________________________________________

 

 

 

*       If
Warrant Shares are to be issued in any name other than that of the registered Holder of the Warrant, then the Holder must include
an opinion of counsel, reasonably satisfactory to the Company, to the effect that such issuance complies with all applicable securities
laws.         

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR VALUE RECEIVED,
___________________________________ hereby sells, assigns and transfers to each assignee set forth below all of the rights of the
undersigned under the Warrant (as defined in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set
opposite the name of such assignee below and in and to the foregoing Warrant with respect to said acquisition rights and the shares
issuable upon exercise of the Warrant:

 

	Name of Assignee

(and social security or federal employer

identification number (if applicable))	 	Address	 	Number of Shares
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

If the total of the
Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests that a new Warrant
evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to the undersigned.

 

	 	Name of Holder (print):       ________________________
	 	(Signature):   ___________________________________
	 	(By:)  _________________________________________
	 	(Title:) ________________________________________
	 	Dated:   ________________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]